Alvotech (ALVO) Operating Expenses (2021 - 2026)
Alvotech (ALVO) posted Operating Expenses of -$50.2 million for Q1 2026, down 110.22% on a QoQ basis from $490.9 million in Q4 2025, and up 11.61% year-over-year from -$45.0 million in Q1 2025.
Alvotech (ALVO) Operating Expenses (2021 - 2026) Analysis & Trends
Alvotech's Operating Expenses history runs 6 years deep, the most recent figure standing at -$50.2 million for Q1 2026.
- Quarterly Operating Expenses rose 11.61% year-over-year to -$50.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $281.7 million (up 159.79% YoY) and the FY2025 annual result came in at $275.1 million, up 16.08% from the prior year.
- Operating Expenses was -$50.2 million for Q1 2026 at Alvotech, down from $490.9 million in the prior quarter.
- Across five years, Operating Expenses topped out at $490.9 million in Q4 2025 and bottomed at -$367.4 million in Q4 2022.
- A 5-year average of -$92.9 million and a median of -$81.5 million in 2025 frame the typical range for Operating Expenses.
- Peak annual rise in Operating Expenses reached 307.12% in 2025, while the deepest fall reached 86773.43% in 2025.
- Alvotech's Operating Expenses stood at -$367.4 million in 2022, then advanced by 21.77% to -$287.4 million in 2023, then rose by 17.52% to -$237.0 million in 2024, then jumped by 307.12% to $490.9 million in 2025, then slumped by 110.22% to -$50.2 million in 2026.
- Business Quant data shows ALVO's Operating Expenses at -$50.2 million in Q1 2026, $490.9 million in Q4 2025, and -$77.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.00 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 788.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 12.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 455.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.24 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 621.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 494.00 Mn |
| 10 | Alvotech | 935.87 Mn | 935.87 Mn | 5.09 Mn | -50.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50.18 Mn |
| Dec 31, 2025 | 490.92 Mn |
| Sep 30, 2025 | -77.54 Mn |
| Jun 30, 2025 | -81.46 Mn |
| Mar 31, 2025 | -56.78 Mn |
| Dec 31, 2024 | -237.03 Mn |
| Sep 30, 2024 | -50.45 Mn |
| Jun 30, 2024 | -126.97 Mn |
| Mar 31, 2024 | -65,356.00 |
| Dec 31, 2023 | -287.39 Mn |
| Aug 31, 2023 | -141.49 Mn |
| Jun 30, 2023 | -141.42 Mn |
| Mar 31, 2023 | -73,062.00 |
| Dec 31, 2022 | -367.36 Mn |
| Aug 31, 2022 | -226.03 Mn |
| Jun 30, 2022 | -154.72 Mn |
| Mar 31, 2022 | -71.31 Mn |
| Dec 31, 2021 | 528.05 Mn |
| Sep 30, 2021 | -76.15 Mn |